EMA Authorised: Avonex (interferon beta-1a) — Biogen Netherlands B.V.

View source ↗

Summary

EMA authorised Avonex (interferon beta-1a) for multiple sclerosis. The marketing authorisation holder is Biogen Netherlands B.V., with a decision date of 16 Oct…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Avonex (Interferon beta-1a)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis. MAH: Biogen Netherlands B.V.. Decision date: 16/10/2025